

METHOD

Open Access



# qKAT: a high-throughput qPCR method for KIR gene copy number and haplotype determination

W. Jiang<sup>1</sup>, C. Johnson<sup>1</sup>, N. Simecek<sup>1</sup>, M. R. López-Álvarez<sup>1</sup>, D. Di<sup>1</sup>, J. Trowsdale<sup>2</sup> and J. A. Traherne<sup>2\*</sup>

## Abstract

Killer cell immunoglobulin-like receptors (KIRs), expressed on natural killer cells and T cells, have considerable biomedical relevance playing significant roles in immunity, pregnancy and transplantation. The *KIR* locus is one of the most complex and polymorphic regions of the human genome. Extensive sequence homology and copy number variation makes *KIRs* technically laborious and expensive to type. To aid the investigation of *KIRs* in human disease we developed a high-throughput, multiplex real-time polymerase chain reaction method to determine gene copy number for each *KIR* locus. We used reference DNA samples to validate the accuracy and a cohort of 1698 individuals to evaluate capability for precise copy number discrimination. The method provides improved information and identifies *KIR* haplotype alterations that were not previously visible using other approaches.

**Keywords:** Killer cell immunoglobulin-like receptor (*KIR*), Copy number variation, Haplotype, Real-time quantitative polymerase chain reaction

## Background

Complex and multi-allelic copy number variation (mCNV) is abundant in the human genome and is a potential source of genetic diversity in relation to disease [1]. Genes involved in immunity and defence seem to be especially prone to mCNV [2], presumably driven by selection pressure from pathogens. Human leukocyte antigen (HLA) DRB, complement component 4 (C4) loci in the MHC and leukocyte immunoglobulin-like receptor (LILR) loci are recognised examples of multicopy gene families with mCNV linked to disease susceptibility [3–7]. Another genomic region of interest in this regard encompasses the killer cell immunoglobulin-like receptor (KIR) genes [8, 9]. KIR were discovered nearly 20 years ago by serological methods [10, 11]. Subsequently they have been shown to have important physiological and biomedical relevance in wide-ranging conditions including pregnancy, infection, autoimmunity, cancer and transplantation [12]. *KIR* associations involve epistasis with their variable cog-

nate HLA ligands. Complex interactions of unlinked loci like these may account for some of the heritability void left by genome-wide association studies (GWAS).

*KIR* genes, which are part of the leukocyte receptor complex (LRC) in human chromosomal region 19q13.4, have evolved rapidly in parallel with their HLA ligands through varying types of selection. As such, *KIR* genes exhibit high diversity in copy number and haplotypes. Unlike normal homologous recombination, chromosomal crossovers in the *KIR* cluster may misalign because the genes are closely arranged head-to-tail and they are homologous in sequence to one another. The process, known as non-allelic homologous recombination (NAHR), generates novel expanded and contracted haplotypes with duplication or deletion of whole genes (between ~11 and 18 kb in size), multiple genes and formation of novel fusion genes [3]. Gene dose effects at the mRNA and protein level have been seen for *KIR* genes, namely *KIR2DL2/L3* and *KIR3DS1*. *KIR* expression is stochastic and the number of NK cells expressing a given *KIR* correlates linearly with the total number of copies of the gene carried by the individual [13]. Thus, the overall responsiveness of the NK cell repertoire directly relates to *KIR* haplotype content. This has implications for

\* Correspondence: jat51@cam.ac.uk

<sup>2</sup>Immunology Division, Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QP, UK  
Full list of author information is available at the end of the article

NK cell-mediated alloreactivity in hematopoietic stem cell transplantation, where donors with a high proportion of alloreactive NK cells have higher levels of cytolytic activity against leukemic cells [14]. Furthermore, *KIR* copy number variation (CNV) has been shown to correlate with protection from certain viruses such as HCV and HIV [15, 16].

The current *KIR* typing techniques that employ specific primers (PCR-SSP) [17–19] or oligonucleotides (PCR-SSO) [20] have drawbacks when applied to large-scale studies of genetically complex diseases; they are time-consuming, expensive and labour-intensive. *KIRs* are refractory to high throughput methods because of extensive sequence homology, allelic and copy number variation. For this reason, *KIR* studies have been limited to date by their relatively small scale and they have been ignored in GWAS to date. In addition, recent studies indicate that structural variations in haplotypes have been overlooked. The conventional methods, such as PCR-SSP, PCR-SSO and MALDI-TOF [21] cannot detect such variation as they lack the ability to quantify gene number, instead providing only ‘presence/absence’ status for a gene.

In this paper, we describe a high-throughput method to determine copy number of each *KIR* locus, using quantitative polymerase chain reaction (PCR) with dual-labelled hydrolysis probes, which we have called qKAT for quantitative *KIR* semi-automated typing. This method can help simplify disease analysis by identifying unusual haplotypes so that the major haplotypes can be analysed separately. We extend the approach to *LILR* loci, demonstrating that the underlying strategy of qKAT offers a model for analysing and visualizing other highly variable mCNV regions.

In real-time PCR, the fluorescent threshold value (cycle of quantification,  $C_q$ ) correlates linearly with logarithmic value of starting DNA copy number [22]. This method can determine the quantity of target DNA sequence specifically and accurately, therefore it has been used extensively for gene quantification, especially in gene expression studies. Compared with complementary DNA quantification in gene expression studies, copy numbers of target gene derived from both chromosomes is slightly different. The relative DNA copy number measured against a reference gene is always an integer ratio. In addition, it is a very small change compared to gene expression ( $2\times$  and  $1.5\times$  for 1–2 and 2–3 copy changes, respectively).

Multiplex quantitative PCR has the advantage of simultaneously amplifying several products in the same tube, using spectrally distinct fluorophores to detect each amplification. The method allows reduction of DNA requirements, reagent costs, human labour and time. Using internal controls increases the reliability of the results. The optimised multiplex assays considerably reduce the cost and setup time by high throughput. Well-to-well

variation is minimised in multiplex PCR since target assay and reference assay are run in the same tube at the same time, providing extra confidence in the results.

## Methods

### Multiplex quantitative PCR assay


For *KIR* assays, ten multiplex quantitative PCR reactions were carried out in a triplex format that included three probes targeting three different amplicons. The optimisations of primer and probe concentrations are shown in Additional file 1: Figures S1 and S2. The overall performance of each reaction was tested using standard curves (see Additional file 1: Figure S3) and the PCR efficiencies of each reaction are given in Additional file 1: Table S1. Each multiplex reaction detects two *KIR* genes and one endogenous reference gene (*STAT6*) that is located on a different chromosome and always has two copies in a diploid genome [23] (Fig. 1) as corroborated using the Database of Genomic Variants (<http://dgv.tcag.ca/dgv/app/>). Altogether, copy numbers of 20 markers were ascertained for 17 *KIR* genes and their important variants (*2DL1*–5, *2DS1*–3, *2DS4* (separate assays for the gene, full-length variant [FL] and deletion variant [del]), *2DS5*, *3DL1*–3, *3DS1*, *2DP1* and *3DP1*). For *3DL1* and *3DL2*, two reactions were used to target different parts of the gene to identify known fusion genes [24]. *LILR* gene copy number was determined using duplex reactions including one *LILR* target and the reference gene (Additional file 1: Table S2).

The reaction mix containing genomic DNA, primers, probes, Taq polymerase and buffer was dispensed into 384-well plates. Five nanograms of each DNA sample were plated into 384-well plates with four replicates. Three control samples of known copy number were included in each run. Multiplex PCR reactions were performed on a Roche LightCycler 480 using absolute quantification settings. Fluorescent signals were collected at the end of each cycle for further analysis.

After PCR amplification,  $C_q$  values were calculated using either the Second Derivative Maximum Method or the Fit Points Method. The copy number was determined by relative quantification analysis using the comparative  $C_q$  method (also known as delta delta  $C_q$  method,  $\Delta\Delta C_q$ ). This method compares the cycle of quantification between the test sample and a calibrator sample with known copy number. In cases where a copy number calibrator sample was not available, the copy number analysis could be performed using the most frequent copy number expected in the samples.

### Primer design

Based on PCR-SSP (PCR amplification with sequence-specific primers), our method used primers with 3' ends specifically matching a nucleotide which is unique to a



given *KIR/LILR* gene. The gene-specific primers were designed to detect all the alleles of the given gene (Additional file 1: Table S3). In this assay, 21 primer pairs were used to detect all 16 *KIR* genes, important *KIR* gene variants and one reference gene. Primers were designed to produce amplicons in the range of 78–210 bp in size. Compared with the previous PCR-SSP and PCR-SSO methods, the short amplicons allowed the PCR reactions to achieve maximum efficiency. The  $T_m$  (melting temperature) of each primer was adjusted to between 48 °C to 57 °C, by adjusting the length of primers.

Initially, 37 primer pairs were designed for all 16 *KIR* genes and some variants. There was more than one reaction for most genes. Gel electrophoresis was used to check each PCR reaction using a known positive DNA sample and two negative DNA samples (for non-framework genes) and a non-template control. Any reactions with non-specific bands, weak amplification and strong primer-dimer were excluded. Due to the limited choice of unique nucleotides for *KIR*-specific priming, some primers were designed with GC content of up to 70.6 %.

#### Probe design

Due to the high sequence similarity between *KIR/LILR* genes, it is difficult to design specific probes. Dual-

labelled probes were designed to exon sequences that are conserved between more than one gene (Additional file 1: Table S4). The same probe could therefore be used in different multiplex assays. Generic probes were feasible because the specificity for each reaction is controlled by the primers and never the same region for different targets was amplified in the same multiplex assay. Using generic probes between different reactions greatly reduced the cost since probes account for a large part of reagent costs. The primer and probe sequences for qKAT are given in Additional file 1 to allow judgment of whether they are appropriate for defining the currently known polymorphisms and variants discovered in the future. Primer and probe combinations used in each reaction are given in Additional file 1: Table S5.

The fluorophores used in the multiplex assays were FAM, Dragonfly Orange and Cy5. The maximum emission wavelengths of the three dyes are: 518 nm, 576 nm and 667 nm, respectively. These three dyes have distant emission spectra, which minimise the fluorescence signal from one dye bleeding into adjacent channels (signal crosstalk). Non-fluorescent black-hole quenchers (BHQ) were used because they have advantages over the other quenchers such as TAMRA, since they absorb the excitation energy from fluorophore and convert it into heat

rather than re-emit this energy as light with a different wavelength. This is useful for multiplex PCR reactions, since there is no emitted light from the quencher to interfere with the reporter fluorophores, resulting in less background signals and hence have better signal/background ratios.

#### Determination DNA copy number using relative quantification analysis

*KIR* and *LILR* copy number of genomic DNA sample was determined using comparative  $C_q$  ( $\Delta\Delta C_q$ ) relative quantification analysis [25–28]. The relationship between calculated copy number without efficiency correction and true copy number is illustrated in Additional file 1: Figure S4. Calculated copy number without efficiency correction and true copy number diverge significantly as the  $\Delta C_q$  in reference assay increases. This explains that apart from PCR efficiency, the  $\Delta C_q$  in reference assay could affect the copy number calculation. The  $\Delta C_q$  in the reference assay actually reflects the difference of DNA concentrations between sample and calibrator. If the DNA concentration is well quantified and controlled in a reasonable range, then the copy number calculation will not be affected much even without PCR efficiency correction. In addition, the parameters from our assays are slightly better than the assumed values. For example, the PCR efficiencies in the experiments have a mean value of 0.9883 with standard deviation of 0.0470. In this case, the ratio change caused by different PCR efficiencies between different genes are even smaller. Therefore, relative quantification using  $\Delta\Delta C_q$  method without efficiency correction could be used to determine DNA copy number.

#### Copy number analysis

Quality control was performed after each PCR run. After checking amplification plots and base lines, failed reactions and outlier values ( $C_q$  of reference assay is greater than 32 or data point > 4 standard deviations from the mean  $\Delta C_q$  of the four replicates) were removed. Then the  $C_q$  values were exported for comparative  $C_q$  calculation using the equations presented above. Zero was assigned to reactions with target assay's  $C_q$  more than 35 and reference assay's  $C_q$  less than 32. The calculation could be performed using either CopyCaller software from Applied Biosystems (Thermo Fisher Scientific) or Excel. CopyCaller provides two additional quality metrics: confidence metric and absolute z-score metric. Confidence metric estimates the confidence that the assigned copy number is the true copy number. Absolute z-score metric estimates how many standard deviations for  $\Delta C_q$  value of one sample varies from the mean  $\Delta C_q$  value assigned with the same copy number. The

calculated copy numbers were rounded up to an integer (known as predicted copy number) for further analysis.

#### Measurement of copy number discrimination

The standard deviation was used to quantify the amount of variation or dispersion in each cluster with the same assigned copy number for each test across different samples ( $n = 1698$ ). As the sample size increases, the  $\Delta\Delta C_q$  value tends to form approximately normal distribution. As for normal distribution, approximately 95 % of the values are within 2 standard deviations from the mean and 99.6 % within 3 standard deviations. Assuming all PCR reactions have 100 % efficiency, the  $\Delta\Delta C_q$  value between one copy and two copies samples will be just 1. To be able to distinguish the difference in more than 99.6 % of the cases, the standard deviations should be less than 0.167 (allowing more than 6 standard deviations within 1). To distinguish the difference in more than 95 % of the cases, the standard deviations should be less than 0.25 (allowing more than 4 standard deviations within 1) (Additional file 1: Table S6). It is progressively more difficult to distinguish the difference between higher copy numbers since the  $\Delta\Delta C_q$  value narrows.

#### Assay validation

Currently there is no gold standard method available for *KIR* typing, especially with copy number information. Data generated from family-based segregation analysis and allele typing could provide information closer to the actual copy number. To validate our method, a reference panel was used including the following DNA samples which had previously been typed with standard methods (PCR-SSP/SSO):

Three extended Centre d'Etude du Polymorphisme Humain (CEPH) families' DNA (Coriell Cell Repositories, NJ, USA) from Utah were included in this study, CEPH/UTAH Pedigree 1332, 1347 and 1416. There are 15 members in each family. Pedigree data of these families are available from dbLRC [29]. In addition, NA10832, NA10861 and NA11994 from other CEPH/UTAH families were also included because they have unusual copy numbers of *KIR* genes.

UCLA *KIR* Exchange panel DNA samples were from UCLA Immunogenetics Center (CA, US, <http://www.hla.ucla.edu/cellDna.htm>). In this study, UCLA69 to UCLA84 were selected. This cohort has consensus *KIR* gene presence and absence data generated by PCR-SSP or PCR-SSO methods from several laboratories around the world. Copy number information is not available for these samples.

Two *KIR* region fully sequenced cell lines, PGF and COX [30], as well as one sequenced CEPH cell line, NA10832 [3], were also included in this study.



A total of 1698 individuals from 339 families from the Human Biological Data Interchange (HBDI) were used to evaluate the precision of a total of 20 *KIR* quantitative PCR assays. The HBDI panel comprises Caucasian (European-ancestry) families with type 1 diabetes from the United States [31]. At present, qKAT is validated for samples of European-origin only.

### ***KIR* haplotype inference in unrelated individuals**

To help analyse samples, we developed a new tool, *KIR* Haplotype Identifier. *KIR* copy number data from qKAT is used as input and through matrix subtraction the program outputs the possible combinations of haplotypes for each sample. The tool is useful as a quick check for identification of novel or unconventional haplotypes in a cohort. The software processes *KIR* copy number sample files submitted by the end user. For each sample, a string of values is created through the concatenation of copy numbers provided (referred to as markersig). A second string is created comprising of a series of regular expressions for each marker (referred to as regex). Each regular expression denotes all possible haplotype values. For example, if sample 1 has markers 'a', 'b' and 'c' each with copy numbers of 2, 1 and 1, respectively, then the markersig string would be 211 and the regex string would be (2|1|0)(1|0)(1|0), i.e. marker 'a' haplotype could be 2 or 1 or 0, marker 'b' haplotype could be 1 or 0 and so on. Each regex string is checked against *KIR* haplotype strings stored in a MySQL database. If a match is found then the associated data (e.g. haplotype, count, frequency, signature, cen motif, te1 motif) is retrieved. The haplotype pair is calculated by subtracting a matrix of the matched string from a matrix of the markersig.

## **Results**

### **Assay validation**

We tested 16 UCLA KIR exchange samples with *KIR* presence/absence data and three CEPH/UTAH families previously studied for *KIR* haplotypes. *KIR* haplotypes were determined by segregation analysis in families (see Additional file 1). For each pedigree, all non-recombinant haplotypes were identified by the Merlin program [32]. The results from *KIR* copy number assays were compared to the *KIR* data generated with previous methods [3, 24, 28]. For CEPH family samples, copy numbers were previously determined by segregation analysis of presence and absence data. Some of the duplicated genes were determined by allele typing [28] and fusion genes were determined by inter-gene PCR [3]. Apart from two exceptions described below, our results showed near complete concordance with previous data.

In pedigree 1416, we confirmed the presence of the extended haplotype carrying duplication of *KIR3DP1*, *KIR2DL4* and *KIR3DL1/S1* genes (Fig. 2). Pedigree 1416

samples NA10834, NA12241, NA12243, NA12244, NA12245, NA12246 and NA12251 showed one less copy in *3DL1* exon 4 than in exon 9. The previous amplicon region of exon 4 was amplified and sequenced using another pair of primers (Forward 5'-CGCTGTGGTGCCTCGA-3' and Reverse 5'-ACCACGATGTCCAGGGGA-3'). Sequencing results revealed a rare allele *3DL1\*056*, which contains a SNP in the probe region that disrupts probe binding. The allele has only been observed in this family [33]. As factored in the original design, the second test for *KIR3DL1* does not miss this rare allele and, therefore, the allele is identified by discordant results between the two tests for *KIR3DL1*.


In pedigree 1347, sample NA11882 showed multiple copies for several genes. However only one offspring is available from this person and it seems that the haplotype carrying duplicated genes has not been transmitted to the next generation. Therefore, it was not visible by previous segregation analysis.

For UCLA KIR Exchange panel DNA samples, only presence and absence information was compared since the original data did not include copy number information. There was 100 % concordance between the two methods for *KIR* presence and absence data. However, additional information was given by copy number data. For example, UCLA76 and UCLA77 have three copies for *3DP1*, *2DL4* and *3DL1/S1* loci. Potentially these two samples carry an extended haplotype, described previously [28] (Fig. 3). UCLA80 and UCLA82 have a deletion from *3DL1* to *3DL2*, which is similar to a haplotype carrying the fusion gene *3DL1/2v* [24] (Fig. 3). For NA10861, NA11994 and the sequenced cell line PGF, COX and NA10832, the copy numbers calculated from our assay were the same as predicted from previous analysis [3, 30].

CNV is seen for *LILRA3* and *LILRA6* loci but not for other *LILR* genes [34]. Copy number of *LILRA6* had previously been determined for the CEPH family samples using Taqman CNV assays [35]. Our results showed complete concordance with this previous data (Additional file 1: Table S7).

### **Measurement of copy number clustering**


Representative examples of clustering results derived for all the *KIR* are given in Fig. 4. The standard deviation in each cluster with the same assigned copy number was used to evaluate ability of clear copy number discrimination in the 20 *KIR* quantitative PCR assays. A total of 1698 DNA samples were used in this analysis (Additional file 1: Table S8). It was possible to confidently distinguish between 3 and 4 copies or even up to 5 copies with the data generated from *KIR* assays. Moreover, most of the data sets displayed a tighter distribution than a Gaussian distribution (D'Agostino–Pearson normality test). In this situation, the standard deviation usually overestimates the data variability.




KIR haplotype inference in unrelated individuals

Family-based segregation analysis can be used to determine gene content on haplotypes. However, in unrelated samples assigning a gene to a haplotype is indefinite when copy number is greater than one for any given

locus. For example, an individual carrying two copies of *KIR3DS1* and one copy of *KIR3DL1* could have two copies of *KIR3DS1* on one haplotype and one copy of *KIR3DS1* on the other haplotype. Alternatively, the individual could have one copy of *KIR3DS1* and *KIR3DL1*





**Fig. 4** Calculated copy number plotted against predicted copy number. Each cluster represents samples assigned with the same copy number. The line and error bar represent mean value and standard deviation of each cluster. The *KIR* gene copy numbers can be determined empirically or, as in this example, by using algorithms incorporated into the CopyCaller software

on the same haplotype with the second copy of *KIR3DS1* on the other haplotype. Approaches for inferring *KIR* haplotype from copy number are detailed in Supplementary Material (Additional file 1: Tables S9–S11). To facilitate analysis of samples for *KIR*, an online tool was developed using Perl and MySQL called ‘*KIR* Haplotype Identifier’ (<http://www.bioinformatics.cimr.cam.ac.uk/haplotypes/>) (Additional file 1: Figure S5). This is a tool for imputing haplotype pairs using observed copy number for each *KIR* loci to help resolve *KIR* haplotypes from unphased genotypes of unrelated individuals. The default haplotype library used by this program is based on European-origin *KIR* gene data but analysis can be carried out using your own *KIR* haplotype frequency data. This is important when analysing a different population, otherwise the software may not give a proper representation of the samples. The tool outputs the possible combinations of haplotypes for each sample based on the gene content of all haplotypes supplied in the haplotype file. Three output files are generated. The first file (Haplotype Results) lists all possible haplotype pairs for each sample, each haplotypes frequency (from the haplotype file) and the predicted combined frequency of each haplotype pair (Additional file 1: Figure S5). The second file is in the same format as Haplotype Results; however, it lists only haplotypes with the highest combined frequency (Haplotype 1 Frequency × Haplotype 2 Frequency) for each sample. The third file (Log file) contains a list of samples where haplotype pairs could not be assigned. In these cases, possible single haplotypes are listed per sample. These results can be visualised by a ‘*KIR* Haplotype Resolution Drawing Tool’ developed using R (Additional file 1: Figure S6). The script is available upon request.

## Discussion

In this paper, we describe a *KIR* typing method based on real-time PCR. This method is able to detect the total number of copies of each *KIR* locus. Clear discrimination between 0, 1, 2, 3 or even 4 copies could be obtained using this method. We extended the approach to *LILR* loci, demonstrating that the qKAT approach can be used to analyse other mCNV loci.

This method is high-throughput and cost-effective. Using a Roche LightCycler 480 real-time PCR instrument with a 384-well Thermal Block Cycler we could complete our PCR assay in 65 min. A Twister II Plate Handler was used as an automation robotics system

(Additional file 1: Figure S7). A MéCour Thermal Plate Stacker was used to keep the stacked plates constantly at 4 °C. With automation, around 22 plates comprising 8448 reactions can be finished within 24 h. Since our full *KIR* typing assay for each sample requires 40 reactions in total (including quadruplicates), this system can produce full *KIR* typing for around 210 samples every day.

Copy number information provided by quantitative PCR may be essential for accurate *KIR* determination. Accurate genotype data are required for population genetic studies and gene dosage effects [36]. Unlike standard genotypes, some *KIR* genes (e.g. *KIR2DL5*, *KIR2DS3* and *KIR2DS5*) can be missing and actual genotype cannot be resolved without copy number information (e.g. -A and AA). Furthermore, recently discovered structural variations make typing even more difficult [3, 24, 28]. For truncated haplotypes carrying a multi-locus deletion, conventional methods can only detect them in a homozygote. For extended haplotypes carrying duplicated loci, typing at the allelic level may be helpful when the multiple alleles are different to each other. Specially designed inter-gene PCRs are useful approaches [3, 24, 37] but from our data it seems there may be many more truncated and extended haplotypes [38]. Nevertheless, none of the approaches could provide precise genotype without family data. Recently, pyrosequencing has been used for *KIR* typing and this can also provide copy number information although there are throughput and cost limitations [24, 39].

Accuracy is extremely important for quantification. We have shown that it is possible for real-time PCR to accurately determine the copy number from genomic DNA. Reference DNA samples were used to validate the accuracy and a large panel of families (1698 samples) to evaluate the precision. Since most CNVs follow Mendelian inheritance, family information can be used to infer copy number in each homologous chromosome after the total copy numbers are obtained from quantitative PCR. This method has been shown to enhance the accuracy of CNV detection [40]. For example, in CEPH family 1347, copy number information assisted in the deduction of gene content for all haplotypes when family data were insufficient to resolve haplotypes for all members with *KIR* presence/absence data. Our method could be further improved by using probabilistic models to increase confidence of chromosome-specific copy number estimates using family information [41]. This approach can be used for the future development of linkage and association tests that require chromosome-specific copy number information. However, like any other PCR-based method, highly polymorphic sequences always pose challenges for designing primers and probes. As we found with the *3DL1\*056* allele in family CEPH1416, there is always the possibility that some

rare alleles may be missed due to polymorphism. The primer and probes were designed to avoid known polymorphism in their annealing sites (Additional file 1: Tables S3 and S5) but as more alleles are described, care should be taken to continually review the assays and redesign the primers/probes as required. If an assay is disrupted by a rare SNP (true allele dropout) this will be identified by the loss of linkage with an adjacent gene that is known to be in high linkage disequilibrium; all *KIR* loci have another *KIR* locus in tight linkage or have an expected copy number, e.g. framework genes are usually always two copies. One can, therefore, check the data against these predefined 'standard *KIR* haplotype rules' (Additional file 1: Table S13) to identify unexpected results and these samples can be further investigated. Alternatively, inconsistencies can be found using the KIR Haplotype Identifier online tool through the appearance of an unusual haplotype in the results. In rare instances when confirmation is required, a second set of assays for each gene can be used for verification (Additional file 1: Table S14).

There are opportunities for further development of the copy number assay. For example, triplex real-time PCR was used in this assay, but it may be possible to achieve up to heptaplex real-time PCR [42] to improve the throughput. Inclusion of an additional reference gene or multicopy reference could provide superior normalisation for DNA input and avoid potential effects of local genomic changes to the reference gene. Supporting our current choice of reference gene, in our screening with qKAT we have not yet identified a sample exhibiting altered *KIR* copy number across all *KIR* loci, including framework genes, indicative of a genomic alteration to the reference gene. Currently, there are other methods to discriminate gene copy number, e.g. DNA microarray, multiplex ligation-dependent probe amplification (MPLA), branched DNA testing, paralogue ratio test (PRT), digital PCR [43] and next generation sequencing (NGS). In addition, *KIR* haplotyping can be achieved through dye-terminator sequencing of *KIR* gene amplicons [44]. Comparing current throughput, cost and complexity of assay setup, quantitative PCR has advantages over the others for *KIR* copy number analysis. Highly repetitive genomic intervals with long stretches of identical sequence, as in the *KIR* locus, have been less amenable to NGS. The present short read lengths obtained by NGS, or the current inaccuracy of long-read length single molecule sequencing, makes sequence assembly and phasing (haplotype-resolution) problematic for characterisation of mCNV loci, especially when more than two copies of a gene are present. As NGS methods improve and become cheaper, we anticipate that this approach will be useful, particularly at increased scale and for precise typing of *KIR* alleles at the nucleotide level. The two approaches will complement



each other and be useful for cross-validation [45]. qKAT offers a simple solution for, as example, initial assessment *KIR* disease association at the gene-level or haplotype-level before investing more time in complex analysis at the allele-level. Once an association has been established, allele resolution typing could be informative if a sufficient number of samples are available for statistically powered analysis. qKAT is simple, one-step and flexible, in that a single gene, or combinations of genes, can be typed alone at minimal cost or as required (e.g. *KIR* A/B haplotype-defining genes). To date, 21 published studies (comprising >20,000 samples in total) including investigations of *KIR* disease association, function, expression and imputation have utilised the method [13, 31, 34, 38, 43, 45–60]. A *KIR* typing service using qKAT has also been established at the Addenbrooke's Hospital Histocompatibility and Immunogenetics (Tissue Typing) laboratory in Cambridge (UK).

## Conclusion

This simple, high-throughput and cost-effective direct *KIR* typing method can be used for disease association studies. In these studies, large numbers of cases and controls are usually needed for *KIR*-HLA interaction analysis. Therefore, this method allows analysis of large-scale studies that were previously labour-intensive, time-consuming and cost-prohibitive. The underlying strategy of qKAT offers a model for analysing any other highly diverse genomic regions of interest.

## Additional file

**Additional file 1:** Supplementary figures S1–S9, supplementary tables S1–S14. (DOCX 2712 kb)

## Abbreviations

BHQ: Black hole quencher; CEPH: Centre d'Etude du Polymorphisme Humain; HBDI: Human Biological Data Interchange; HLA: Human leukocyte antigen; HWE: Hardy–Weinberg Equilibrium; KIR: Killer immunoglobulin-like receptor; LRC: Leukocyte receptor complex; MALDI-TOF: Matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry; mCNV: Multi-allelic copy number variation; MPLA: Multiplex ligation-dependent probe amplification; NAHR: Non-allelic homologous recombination; PCR-SSO: Sequence-specific oligonucleotide PCR; PCR-SSP: Sequence-specific primed PCR; qKAT: Quantitative KIR semi-automated typing

## Acknowledgements

We thank Janelle Noble for providing DNA samples and Jyothi Jayaraman for technical assistance.

## Funding

This work was funded by the Medical Research Council (MRC) and the Wellcome Trust with partial funding from the National Institute of Health (NIH) Cambridge Biomedical Research Centre and NIH Research Blood and Transplant Research Unit (NIHR BTRU) in Organ Donation and Transplantation at the University of Cambridge in collaboration with Newcastle University and in partnership with NHS Blood and Transplant (NHSBT). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health or NHSBT.

## Availability of data and material

The data generated and analysed during this study are available from the corresponding author on request.

## Authors' contributions

WJ, MRLA and JAT designed the assays, performed experiments, analysed the data and wrote the manuscript. CJ contributed to experimental design as well as acquisition and analysis of the data. NS, DD and JAT developed the analysis tools. JT contributed to drafting the manuscript. All authors read and approved the final manuscript.

## Competing interests

The authors declare that they have no competing interests.

## Consent for publication

Not applicable.

## Ethics approval and consent to participate

Not applicable. The biobank genomic DNA samples from immortalised cell lines were received codified and untraceable to an individual (fully anonymised). The biobanks (HBDI, Coriell Repositories, UCLA International KIR Exchange) hold the original REC approvals for generic research use and the consent documentation.

## Author details

<sup>1</sup>Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Wellcome Trust/MRC Building, Hills Road, Cambridge CB2 0XY, UK. <sup>2</sup>Immunology Division, Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QP, UK.

Received: 4 August 2016 Accepted: 15 September 2016

Published online: 29 September 2016

## References

- Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, et al. Global variation in copy number in the human genome. *Nature*. 2006;444(7118):444–54.
- Conrad DF, Andrews TD, Carter NP, Hurler ME, Pritchard JK. A high-resolution survey of deletion polymorphism in the human genome. *Nat Genet*. 2006;38(1):75–81.
- Traherne JA, Martin M, Ward R, Ohashi M, Pellett F, Gladman D, et al. Mechanisms of copy number variation and hybrid gene formation in the KIR immune gene complex. *Hum Mol Genet*. 2010;19(5):737–51.
- Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, et al. Schizophrenia risk from complex variation of complement component 4. *Nature*. 2016;530(7589):177–83.
- Yang Y, Chung EK, Wu YL, Savelli SL, Nagaraja HN, Zhou B, et al. Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. *Am J Hum Genet*. 2007;80(6):1037–54.
- Olsson LM, Holmdahl R. Copy number variation in autoimmunity—importance hidden in complexity? *Eur J Immunol*. 2012;42(8):1969–76.
- Hirayasu K, Arase H. Functional and genetic diversity of leukocyte immunoglobulin-like receptor and implication for disease associations. *J Hum Genet*. 2015;60(11):703–8.
- Trowsdale J, Jones DC, Barrow AD, Traherne JA. Surveillance of cell and tissue perturbation by receptors in the LRC. *Immunol Rev*. 2015;267(1):117–36.
- Pyo CW, Guethlein LA, Vu Q, Wang R, Abi-Rached L, Norman PJ, et al. Different patterns of evolution in the centromeric and telomeric regions of group A and B haplotypes of the human killer cell Ig-like receptor locus. *PLoS One*. 2010;5(12):e15115.
- Litwin V, Gumperz J, Parham P, Phillips JH, Lanier LL. NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. *J Exp Med*. 1994;180(2):537–43.
- Moretta A, Vitale M, Bottino C, Orengo AM, Morelli L, Augugliaro R, et al. P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. *J Exp Med*. 1993;178(2):597–604.

12. Parham P. MHC class I molecules and KIRs in human history, health and survival. *Nat Rev Immunol*. 2005;5(3):201–14.
13. Beziat V, Traherne JA, Liu LL, Jayaraman J, Enqvist M, Larsson S, et al. Influence of KIR gene copy number on natural killer cell education. *Blood*. 2013;121(23):4703–7.
14. Moretta L, Locatelli F, Pende D, Marcenaro E, Mingari MC, Moretta A. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. *Blood*. 2011;117(3):764–71.
15. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. *Science*. 2004;305(5685):872–4.
16. Pelak K, Need AC, Fellay J, Shianna KV, Feng S, Urban TJ, et al. Copy number variation of KIR genes influences HIV-1 control. *PLoS Biol*. 2011;9(11):e1001208.
17. Vilches C, Castano J, Gomez-Lozano N, Estefania E. Facilitation of KIR genotyping by a PCR-SSP method that amplifies short DNA fragments. *Tissue Antigens*. 2007;70(5):415–22.
18. Ashouri E, Ghaderi A, Reed EF, Rajalingam R. A novel duplex SSP-PCR typing method for KIR gene profiling. *Tissue Antigens*. 2009;74(1):62–7.
19. Martin MP, Carrington M. KIR locus polymorphisms: genotyping and disease association analysis. *Methods Mol Biol* (Clifton, NJ). 2008;415:49–64.
20. Nong T, Saito K, Blair L, Tarisani C, Lee JH. KIR genotyping by reverse sequence-specific oligonucleotide methodology. *Tissue Antigens*. 2007;69 Suppl 1:92–5.
21. Houtchens KA, Nichols RJ, Ladner MB, Boal HE, Sollars C, Geraghty DE, et al. High-throughput killer cell immunoglobulin-like receptor genotyping by MALDI-TOF mass spectrometry with discovery of novel alleles. *Immunogenetics*. 2007;59(7):525–37.
22. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. *Genome Res*. 1996;6(10):986–94.
23. Degenhardt JD, de Candia P, Chabot A, Schwartz S, Henderson L, Ling B, et al. Copy number variation of CCL3-like genes affects rate of progression to simian-AIDS in Rhesus Macaques (*Macaca mulatta*). *PLoS Genet*. 2009;5(1):e1000346.
24. Norman PJ, Abi-Rached L, Gendzekhadze K, Hammond JA, Moesta AK, Sharma D, et al. Meiotic recombination generates rich diversity in NK cell receptor genes, alleles, and haplotypes. *Genome Res*. 2009;19(5):757–69.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>−(Delta Delta C(T))</sup> Method. *Methods*. 2001;25(4):402–8.
26. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res*. 2001;29(9):e45.
27. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. *Nat Protoc*. 2008;3(6):1101–8.
28. Martin MP, Bashirova A, Traherne J, Trowsdale J, Carrington M. Cutting edge: expansion of the KIR locus by unequal crossing over. *J Immunol*. 2003;171(5):2192–5.
29. Helmberg W, Feolo M, Dunivin R. dbLRC-KIR, a new specialised database for genes of the leucocyte receptor complex. *Hum Immunol*. 2005;66(8, Supplement 1):17.
30. Horton R, Coghill P, Miretti MM, Sambrook JG, Traherne JA, Ward R, et al. The LRC haplotype project: a resource for killer immunoglobulin-like receptor-linked association studies. *Tissue Antigens*. 2006;68(5):450–2.
31. Traherne JA, Jiang W, Valdes AM, Hollenbach JA, Jayaraman J, Lane JA, et al. KIR haplotypes are associated with late-onset type 1 diabetes in European-American families. *Genes Immun*. 2016;17(1):8–12.
32. Abecasis GR, Cherny SS, Cookson WO, Cardon LR. Merlin—rapid analysis of dense genetic maps using sparse gene flow trees. *Nat Genet*. 2002;30(1):97–101.
33. Sun JY, Oki A, Senitzer D. Alleles and intron polymorphism of KIR3DL1 shown by combination of allele group-specific primers and sequencing. *Tissue Antigens*. 2008;72(6):578–80.
34. Lopez-Alvarez MR, Jones DC, Jiang W, Traherne JA, Trowsdale J. Copy number and nucleotide variation of the LILR family of myelomonocytic cell activating and inhibitory receptors. *Immunogenetics*. 2014;66(2):73–83.
35. Bashirova AA, Apps R, Vince N, Mochalova Y, Yu XG, Carrington M. Diversity of the human LILRB3/A6 locus encoding a myeloid inhibitory and activating receptor pair. *Immunogenetics*. 2014;66(1):1–8.
36. Li H, Pascal V, Martin MP, Carrington M, Anderson SK. Genetic control of variegated KIR gene expression: polymorphisms of the bi-directional KIR3DL1 promoter are associated with distinct frequencies of gene expression. *PLoS Genet*. 2008;4(11):e1000254.
37. Gomez-Lozano N, Estefania E, Williams F, Halfpenny I, Middleton D, Solis R, et al. The silent KIR3DP1 gene (CD158c) is transcribed and might encode a secreted receptor in a minority of humans, in whom the KIR3DP1, KIR2DL4 and KIR3DL1/KIR3DS1 genes are duplicated. *Eur J Immunol*. 2005;35(1):16–24.
38. Jiang W, Johnson C, Jayaraman J, Simecek N, Noble J, Moffatt MF, et al. Copy number variation leads to considerable diversity for B but not A haplotypes of the human KIR genes encoding NK cell receptors. *Genome Res*. 2012;22(10):1845–54.
39. Moreland AJ, Guethlein LA, Reeves RK, Broman KW, Johnson RP, Parham P, et al. Characterization of killer immunoglobulin-like receptor genetics and comprehensive genotyping by pyrosequencing in rhesus macaques. *BMC Genomics*. 2011;12:295.
40. Kosta K, Sabroe I, Goke J, Nibbs RJ, Tsanakas J, Whyte MK, et al. A Bayesian approach to copy-number-polymorphism analysis in nuclear pedigrees. *Am J Hum Genet*. 2007;81(4):808–12.
41. Wang K, Chen Z, Tadesse MG, Glessner J, Grant SF, Hakonarson H, et al. Modeling genetic inheritance of copy number variations. *Nucleic Acids Res*. 2008;36(21):e138.
42. Köppl R, Zimmerli F, Breitenmoser A. Heptaplex real-time PCR for the identification and quantification of DNA from beef, pork, chicken, turkey, horse meat, sheep (mutton) and goat. *Eur Food Res Technol*. 2009;230(1):125–33.
43. Roberts CH, Jiang W, Jayaraman J, Trowsdale J, Holland MJ, Traherne JA. Killer-cell Immunoglobulin-like Receptor gene linkage and copy number variation analysis by droplet digital PCR. *Genome Med*. 2014;6(3):20.
44. Pyo CW, Wang R, Vu Q, Cereb N, Yang SY, Duh FM, et al. Recombinant structures expand and contract inter and intragenic diversification at the KIR locus. *BMC Genomics*. 2013;14:89.
45. Norman PJ, Hollenbach JA, Nemat-Gorgani N, Marin WM, Norberg SJ, Ashouri E, et al. Defining KIR and HLA class I genotypes at highest resolution via high-throughput sequencing. *Am J Hum Genet*. 2016;99(2):375–91.
46. Beziat V, Liu LL, Malmberg JA, Ivarsson MA, Sohlberg E, Björklund AT, et al. NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. *Blood*. 2013;121(14):2678–88.
47. Nakimuli A, Chazara O, Farrell L, Hiby SE, Tukwasibwe S, Kneen O, et al. Killer cell immunoglobulin-like receptor (KIR) genes and their HLA-C ligands in a Ugandan population. *Immunogenetics*. 2013;65(11):765–75.
48. Pontikos N, Smyth DJ, Schuilenburg H, Howson JM, Walker NM, Burren OS, et al. A hybrid qPCR/SNP array approach allows cost efficient assessment of KIR gene copy numbers in large samples. *BMC Genomics*. 2014;15:274.
49. Beziat V, Traherne J, Malmberg JA, Ivarsson MA, Björkstén NK, Retiere C, et al. Tracing dynamic expansion of human NK-cell subsets by high-resolution analysis of KIR repertoires and cellular differentiation. *Eur J Immunol*. 2014;44(7):2192–6.
50. Fosby B, Naess S, Hov JR, Traherne J, Boberg KM, Trowsdale J, et al. HLA variants related to primary sclerosing cholangitis influence rejection after liver transplantation. *World J Gastroenterol*. 2014;20(14):3986–4000.
51. Nemat-Gorgani N, Edinur HA, Hollenbach JA, Traherne JA, Dunn PP, Chambers GK, et al. KIR diversity in Maori and Polynesians: populations in which HLA-B is not a significant KIR ligand. *Immunogenetics*. 2014;66(11):597–611.
52. Jones DC, Peacock S, Hughes D, Traherne JA, Allen RL, Barnardo MC, et al. Killer immunoglobulin-like receptor gene repertoire influences viral load of primary human cytomegalovirus infection in renal transplant patients. *Genes Immun*. 2014;15(8):562–8.
53. Cassidy S, Mukherjee S, Myint TM, Mbiribindi B, North H, Traherne J, et al. Peptide selectivity discriminates NK cells from KIR2DL2- and KIR2DL3-positive individuals. *Eur J Immunol*. 2015;45(2):492–500.
54. Nakimuli A, Chazara O, Hiby SE, Farrell L, Tukwasibwe S, Jayaraman J, et al. A KIR B centromeric region present in Africans but not Europeans protects pregnant women from pre-eclampsia. *Proc Natl Acad Sci U S A*. 2015;112(3):845–50.
55. Dunphy SE, Guinan KJ, Chorcara CN, Jayaraman J, Traherne JA, Trowsdale J, et al. 2DL1, 2DL2 and 2DL3 all contribute to KIR phenotype variability on human NK cells. *Genes Immun*. 2015;16(5):301–10.
56. Hydes TJ, Moesker B, Traherne JA, Ashraf S, Alexander GJ, Dimitrov BD, et al. The interaction of genetic determinants in the outcome of HCV infection: evidence for discrete immunological pathways. *Tissue Antigens*. 2015;86(4):267–75.
57. Vukcevic D, Traherne JA, Naess S, Ellinghaus E, Kamatani Y, Dilthey A, et al. Imputation of KIR types from SNP variation data. *Am J Hum Genet*. 2015;97(4):593–607.

58. Jamil KM, Hydes TJ, Cheent KS, Cassidy SA, Traherne JA, Jayaraman J, et al. STAT4-associated natural killer cell tolerance following liver transplantation. *Gut*. 2016. doi:10.1136/gutjnl-2015-309395.
59. Liu LL, Landskron J, Ask EH, Enqvist M, Sohlberg E, Traherne JA, et al. Critical role of CD2 co-stimulation in adaptive natural killer cell responses revealed in NKG2C-deficient humans. *Cell Rep*. 2016;15(5):1088–99.
60. Lopez-Alvarez MR, Jiang W, Jones DC, Jayaraman J, Johnson C, Cookson WO, et al. LILRA6 copy number variation correlates with susceptibility to atopic dermatitis. *Immunogenetics*. 2016;68(9):743–7.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

